Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression

Show full item record



Permalink

http://hdl.handle.net/10138/236227

Citation

Kraus , C , Castrén , E , Kasper , S & Lanzenberger , R 2017 , ' Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression ' , Neuroscience & Biobehavioral Reviews , vol. 77 , pp. 317-326 . https://doi.org/10.1016/j.neubiorev.2017.03.007

Title: Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression
Author: Kraus, Christoph; Castrén, Eero; Kasper, Siegfried; Lanzenberger, Rupert
Contributor organization: Neuroscience Center
Eero Castren / Principal Investigator
Date: 2017-06
Language: eng
Number of pages: 10
Belongs to series: Neuroscience & Biobehavioral Reviews
ISSN: 0149-7634
DOI: https://doi.org/10.1016/j.neubiorev.2017.03.007
URI: http://hdl.handle.net/10138/236227
Abstract: Serotonin modulates neuroplasticity, especially during early life, and dysfunctions in both systems likewise contribute to pathophysiology of depression. Recent findings demonstrate that serotonin reuptake inhibitors trigger reactivation of juvenile-like neuroplasticity. How these findings translate to clinical antidepressant treatment in major depressive disorder remains unclear. With this review, we link preclinical with clinical work on serotonin and neuroplasticity to bring two pathophysiologic models in clinical depression closer together. Dysfunctional developmental plasticity impacts on later-life cognitive and emotional functions, changes of synaptic serotonin levels and receptor levels are coupled with altered synaptic plasticity and neurogenesis. Structural magnetic resonance imaging in patients reveals disease-state-specific reductions of gray matter, a marker of neuroplasticity, and reversibility upon selective serotonin reuptake inhibitor treatment. Translational evidence from magnetic resonance imaging in animals support that reduced densities and sizes of neurons and reduced hippocampal volumes in depressive patients could be attributable to changes of serotonergic neuroplasticity. Since ketamine, physical exercise or learning enhance neuroplasticity, combinatory paradigms with selective serotonin reuptake inhibitors could enhance clinical treatment of depression. (C) 2017 Elsevier Ltd. All rights reserved.
Subject: Neuroplasticity
Serotonin
Depression
Neurogenesis
Structural magnetic resonance imaging
Voxel-based morphometry
Brain-derived neurotrophic factor
VOXEL-BASED MORPHOMETRY
ADULT HIPPOCAMPAL NEUROGENESIS
DORSOLATERAL PREFRONTAL CORTEX
LONG-TERM DEPRESSION
SYNAPTIC PLASTICITY
MAJOR DEPRESSION
DENTATE GYRUS
NEUROTROPHIC FACTOR
5-HT1A RECEPTORS
MOOD DISORDERS
3112 Neurosciences
3124 Neurology and psychiatry
Peer reviewed: Yes
Rights: unspecified
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Serotonin_and_neuroplasticity.pdf 1.190Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record